"Paxlovid's Underuse Despite Ability to Reduce Severe COVID-19 Cases"

Paxlovid, an antiviral treatment for COVID-19, is proven to reduce the risk of severe illness and hospitalization, but it is underused due to high cost, doctors' hesitation to prescribe, and concerns about drug interactions. The drug was initially free but now has a list price of $1,390, making it inaccessible for many. Additionally, reimbursement rates and insurance coverage issues are hindering its availability. A study found that Paxlovid was disproportionately given to lower-risk patients, potentially preventing thousands of COVID-19 deaths if properly utilized.